Regulatory FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development FDAThe U.S.RegulatoryGene Therapy PlatformRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) FDA The U.S. RegulatoryGene Therapy PlatformRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA renews criticism of trial sponsors over transparencyNext: Lilly investing billions to prepare for overseas oral GLP-1 launches Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
